COR · 8-K · 20260805PR000032

Products and Technology

Cencora, Inc. · 2026-08-05 · Importance 23 · Surprise 24

Product mix included increased sales of specialty pharmaceuticals to health systems and physician practices and higher sales of GLP-1 products used for diabetes and/or weight loss. GLP-1 products carry lower gross profit margins, creating a mix-related offset to margin expansion. The company also cited investments in specialty and digital transformation as capabilities supporting customers across the healthcare ecosystem.